NCT02235701View on ClinicalTrials.gov

Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

September 2, 2014

Primary Completion Date

May 1, 2018

Study Completion Date

May 1, 2018

Conditions
Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma
Interventions
DRUG

170 mg/m2 aldoxorubicin

administered at 170 mg/m2 plus 1 gm/m2/day ifosfamide by continuous intravenous infusion for up to 14 days on Day 1 every 28 days

DRUG

250 mg/m2 aldoxorubicin

administered at 250 mg/m2 plus 1 gm/m2/day ifosfamide by continuous intravenous infusion for up to 14 days on Day 1 every 28 days

Trial Locations (1)

90403

Sarcoma Oncology Center, Santa Monica

Sponsors

Lead Sponsor

ImmunityBio, Inc.
All Listed Sponsors
lead

ImmunityBio, Inc.

INDUSTRY